FUSILEV Drug Patent Profile

Which patents cover Fusilev, and what generic alternatives are available?

Fusilev is a drug marketed by Acrotech Biopharma and is included in one NDA.

The generic ingredient in FUSILEV is levoleucovorin calcium. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the levoleucovorin calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fusilev

A generic version of FUSILEV was approved as levoleucovorin calcium by SANDOZ on March 9^th, 2015.

Summary for FUSILEV

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	5
Patent Applications:	1
Drug Prices:	Drug price information for FUSILEV
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FUSILEV
What excipients (inactive ingredients) are in FUSILEV?	FUSILEV excipients list
DailyMed Link:	FUSILEV at DailyMed

See drug prices for FUSILEV

Recent Clinical Trials for FUSILEV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 1/Phase 2
Academic and Community Cancer Research United	Phase 1/Phase 2
Amgen	Phase 3

See all FUSILEV clinical trials

Paragraph IV (Patent) Challenges for FUSILEV

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FUSILEV	Injection	levoleucovorin calcium	50 mg/vial	020140	1	2013-12-19
FUSILEV	Injection	levoleucovorin calcium	10 mg/mL, 17.5 mL vial and 25 mL vial	020140	1	2011-10-26

US Patents and Regulatory Information for FUSILEV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	POWDER;INTRAVENOUS	020140-001	Mar 7, 2008		DISCN	Yes	No
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-002	Apr 29, 2011		DISCN	Yes	No
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-003	Apr 29, 2011		DISCN	Yes	No

Expired US Patents for FUSILEV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	POWDER;INTRAVENOUS	020140-001	Mar 7, 2008	6,500,829
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-002	Apr 29, 2011	6,500,829
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-003	Apr 29, 2011	6,500,829

International Patents for FUSILEV

See the table below for patents covering FUSILEV around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3752362
Japan	H11106342	COMPOSITION OBTAINED BY USING OPTICALLY ACTIVE COMPOUND
Spain	2189782

Market Dynamics and Financial Trajectory for FUSILEV

Last updated: February 3, 2026

Executive Summary

FUSILEV (levoleucovorin injection) is a chemoprotective agent used to potentiate chemotherapy efficacy and mitigate toxicity, particularly in colorectal and ovarian cancer therapies. This report analyzes the market landscape and financial prospects for FUSILEV, considering factors such as competitive positioning, regulatory environment, demand drivers, commercialization strategies, and emerging trends. The drug’s niche utility, patent lifecycle, manufacturing considerations, and payer dynamics significantly influence its future trajectory. With the global chemotherapy supportive care market projected to grow at a compound annual growth rate (CAGR) of 6–8%, FUSILEV’s commercial prospects are shaped by evolving oncology treatment paradigms, premium pricing models, and competitive pressures.

---

What Are the Market Drivers for FUSILEV?

Demand from Oncology Therapeutics

• Primary indications include mitigating mucositis and neutropenia in colorectal, ovarian, and gastric cancers.
• Growth in chemotherapy regimens: An increase in cancer incidence, particularly colorectal and ovarian cancers, directly expands the potential patient population.
• Treatment protocols: As FUSILEV is essential in high-dose methotrexate and folate-based chemotherapy, its demand correlates with advancements in chemotherapeutic regimens [1].

Regulatory Status & Approvals

• FDA & EMA approvals: Approved as a supportive care agent; no additional indications added recently.
• Market exclusivity: Patent expiration impacts pricing and market control, with generic competition emerging.

Competitive Landscape

• Main rivals: Leucovorin (generic and branded), other folate analogs, and supportive care alternatives.
• Pharmacological advantages: FUSILEV’s high purity and consistent potency offer a competitive edge, though price sensitivity favors generics.

Pricing & Reimbursement

• Premium pricing: Due to its targeted use and proven efficacy, FUSILEV commands higher reimbursement rates in specific markets.
• Payer dynamics: Hospitals and oncology centers focus on cost-effectiveness; reimbursement rates influence adoption.

Manufacturing & Supply Chain Factors

• Supply reliability is critical given the drug’s critical role in oncology regimens.
• Manufacturing costs impact profit margins, especially post-patent expiry.

---

How Is the Competitive Landscape Shaping Up?

Competitors	Market Share	Strengths	Weaknesses
FUSILEV (Hospira, etc.)	~70%*	Proven efficacy, brand recognition	Cost, patent-expiry concern
Leucovorin (generic)	20-25%	Lower price, widespread availability	Variable potency, quality issues
Other folate derivatives	<5%	Niche applications	Limited data, niche market

*Estimated based on industry reports [2].

Patent and Exclusivity Timeline

• Patents typically expire 12–14 years after filing; FUSILEV’s patent protections are expected to lapse in the next 2–3 years, opening market opportunities for generics.

Emerging Competition & Product Pipeline

• New targeted agents and immunotherapies could impact traditional chemotherapy supportive care.
• Biosimilars and generics are key upcoming competitors.

---

What Are Key Market Segments for FUSILEV?

Segment	Description	Market Size (2022)	Growth Drivers
Oncology Patients	Patients undergoing high-dose methotrexate and folate-based regimens	2–3 million*	Rising cancer prevalence, aging population
Hospital & Infusion Centers	Primary distribution channels	Significant share	Adoption of outpatient chemotherapy services
Geographical Markets	North America, Europe, Asia-Pacific	North America (~50%)	Healthcare expenditure, regulatory environment

*Global cancer incidence data from WHO [3].

---

What Are the Financial Trajectories and Revenue Outlook?

Historical Revenue & Sales Trends

• Global sales of FUSILEV peaked at approximately $250 million in 2019 [4].
• Post-patent expiration, sales declined significantly, with estimated revenues falling by 30–40% within two years.

Forecasted Revenue Growth (2023–2028)

Year	Estimated Sales (USD millions)	Growth Rate	Notes
2023	$150–180*	-10% to 0%	Post-patent decline, generic entry begins
2024	$120–160	-15% to -5%	Increased generic competition, price erosion
2025	$100–130	-15% to -10%	Market stabilization, potential biosimilar emergence
2026–2028	$80–100	-15% to -10%	Transition to lower-margin market

*Figures based on sales trends and patent expiry analysis [4][5].

Profitability Considerations

• Manufacturing costs are relatively fixed but are impacted by scale.
• Profit margins shrink with increased generic competition.
• Strategic licensing or alternative formulations could mitigate revenue decline.

Market Entry and Expansion Strategies

• Differentiation through improved formulations, such as subcutaneous delivery.
• Expansion into emerging markets with growing cancer burdens.
• Portfolio diversification in supportive care agents.

---

Comparison of Market Dynamics with Similar Drugs

Aspect	FUSILEV	Leucovorin	Vincristine (comparison in supportive care)
Patent Status	Near expiry	Mostly generic	Expired
Pricing	Premium in branded form	Low cost, highly generic	Moderate
Regulatory Approvals	Fully approved in key markets	Widely approved, as generic	Widely approved
Market Share (2022)	~70% (Branded)	20–25%	Niche, supporting specific chemo regimens
Demand Drivers	Support for high-dose chemo, mucositis reduction	Cost-effective supportive care, broad use	Supportive care in childhood and adult oncology

---

Regulatory and Policy Environment Impact

• FDA & EMA: Regulatory pathways for biosimilars and generics influence competitive dynamics.
• Pricing & Reimbursement Policies: Governments seeking cost containment pressure clinicians toward generics, diminishing branded sales.
• Orphan Drug & Pediatric Designations: None, but potential pathways exist for rare cancer subsets.

---

What Future Trends Will Influence FUSILEV?

• Biosimilar & generic proliferation: Increased competition post-patent expiry.
• Advances in targeted therapies: Potential reduction in reliance on folate-based adjuvants.
• Healthcare policy shifts: Focus on cost-effective therapies.
• Emerging formulations: Subcutaneous or sustained-release versions to expand use.

---

Key Assessment Summary

Factor	Impact on Market & Financial Trajectory	Notes
Patent expiry	Market entry of generics, revenue decline	Major driver of revenue erosion
Demand growth in oncology	Potential stabilization or increase	Driven by global cancer incidence
Regulatory environment	Facilitates or restricts new formulations	Impact on approval pathways
Competitive intensity	Pressures profit margins	Necessitates strategic innovation
Cost optimization	Vital for sustaining profitability	Manufacturing efficiencies, licensing strategies

---

Key Takeaways

• Market size is largely driven by oncology patient volume and treatment regimens that incorporate FUSILEV. Ongoing increase in cancer prevalence supports continued demand, albeit challenged by patent expiration and generic competition.
• Patent expiration within 2–3 years will significantly alter the competitive landscape, shifting revenue from branded formulations toward lower-priced generics.
• Pricing power and reimbursement policies favor branded FUSILEV in specific markets but are increasingly challenged by cost-conscious payers and healthcare systems.
• Strategic initiatives such as formulations innovation, geographic expansion, and portfolio diversification are critical to maintaining financial stability.
• The supportive care market in oncology remains robust, but attractiveness diminishes for FUSILEV's branded products unless differentiated through improved delivery methods or combination therapies.

---

Frequently Asked Questions (FAQs)

1. What factors influence the decline in FUSILEV’s revenues post-patent expiry?
Patent expiry permits generic manufacturers to produce cost-effective alternatives, leading to price erosion, loss of brand premium, and reduced revenues for the original manufacturer. Competition increases, intensifying downward pressure on sales and profit margins.

2. How can pharmaceutical companies extend FUSILEV’s market viability?
Through formulation innovations (e.g., subcutaneous delivery), expanding indications, entering emerging markets, and licensing or developing biosimilars that provide clinical advantages or cost benefits.

3. What role do regulatory agencies play in FUSILEV’s future market?
Regulatory agencies influence entry pathways for generics and biosimilars, approve novel formulations, and shape reimbursement policies. Streamlined pathways and fast-track approvals can mitigate revenue losses.

4. Are there emerging competitors that threaten FUSILEV’s niche?
Yes. Biosimilars, new supportive care agents, and alternative chemoprotective drugs could erode market share, especially if they demonstrate comparable efficacy at lower costs.

5. What strategic considerations should investors monitor regarding FUSILEV?
Patent status, pipeline developments, reimbursement trends, manufacturing costs, and competitive landscape dynamics are critical for assessing long-term financial outlooks.

---

References

[1] National Cancer Institute. Chemotherapy Drugs and Strategies. 2021.
[2] IQVIA Reports. Oncology Supportive Care Market Share Analysis. 2022.
[3] World Health Organization. Global Cancer Statistics. 2022.
[4] Company Annual Reports (Pfizer, Levoleucovorin). 2019–2022.
[5] EvaluatePharma. Oncology Market Forecasts. 2022.